PubMed · 8094571
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
H Sasaki, S Itabashi, T Fukushima, K Sekizawa. 1993. [Chronic obstructive pulmonary disease (COPD)].. https://pubmed.ncbi.nlm.nih.gov/8094571/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
1. In cell-attached patches formed on the apical membrane of fetal alveolar epithelium, terbutaline (a specific beta2-adrenergic agonist) increased the open probability (Po) of an amiloride-sensitive Na+-permeable non-selective cation (NSC) channel (control, 0.03 +/- 0.04; terbutaline, 0.62 +/- 0.18; n = 8, P < 0. 00001) by increasing the mean open time 100-fold without any significant change in the mean closed time and without any change in the single channel conductance (control, 27.8 +/- 2.3 pS; terbutaline, 28.2 +/- 2.1 pS; n = 8). 2. The Po of the unstimulated channel increased when the apical membrane was depolarized due to a decrease in the closing rate and an increase in the opening rate, while the Po of the terbutaline-stimulated channel did not depend on the membrane potential. 3. Increased cytosolic [Ca2+] also increased the Po of the channel in a manner consistent with one Ca2+-binding site on the cytosolic surface of the channel. Terbutaline increased the sensitivity of the channel to cytosolic Ca2+ by shifting the concentration of cytosolic Ca2+ ([Ca2+]c) required for half-maximal activation to a lower [Ca2+]c value, leading to an increase in Po. 4. An increase in the cytosolic Cl- concentration ([Cl-]c) decreased the Po of the channel consistent with two Cl--binding sites by increasing the closing rate without any significant change in the opening rate. Terbutaline increased Po by reducing the effect of cytosolic Cl- to promote channel closing. 5. Taken together, these observations indicate that terbutaline activates a Ca2+-activated, Cl--inhibitable, amiloride-sensitive, Na+-permeable NSC channel in fetal rat alveolar epithelium in two ways: first, through an increase in Ca2+ sensitivity, and second, through a reduction in the effect of cytosolic Cl- to promote channel closing.
In a previous publication it was shown that 1 microgram colchicine injected into the diagonal band of Broca (DBB) produced a significant decrease in femoral artery blood pressure (and/or volume) measured in urethane-anaesthetised rats. In order to test if the central catecholamines were involved in this effect, guide cannulae were implanted in the DBB and a catheter in the femoral artery. On-line pressure recordings were taken before during and after alpha1, alpha2 and beta adrenoreceptor agonists and antagonists were injected into the region of the DBB of non-anaesthetised and urethane anaesthetised male Wistar rats with and without injection of colchicine. Arterial pressure was significantly increased in the non-anaesthetised rats (114.6+/-2.6 n=11 vs. 149.3+/-3.3 mmHg n=12, p<0.01) yet significantly reduced (82.0+/-3.9 n=11 vs. 63.8+/-4.5 mmHg n=12, p<0.01) in the urethane treated rats by the alpha2 agonist clonidine. The alpha2 antagonist yohimbine blocked these effects in both preparations. In contrast, the beta adrenoreceptor agonist isoprenaline produced a significant decrease in arterial pressure in both preparations (107.7+/-3.9 n=11 vs. 85.9+/-4.0 mmHg n=12, p<0.01) (102.6+/-6.7 n=11 vs. 81.7+/-3.4 mmHg n=12, p<0.01) and this effect was blocked by the beta antagonist propranolol. Colchicine injected into the DBB abolished the effects of the alpha2 agonist and antagonist in the non-anaesthetised but not the anaesthetised rats. The responses to the beta agonist and antagonist were not greatly affected by the colchicine in the non-anaesthetised rats whereas in the anaesthetised rat beta agonist injection tended to totally depress arterial pressure. These results suggest that the sympathetic nervous system in the DBB plays a significant role in the central control of arterial pressure and that the alpha2 component is significantly affected by the state of anaesthesia.
Ventricular function may improve after coronary artery bypass grafting (CABG) in patients with ischemic cardiomyopathy depending on the amount of contractile myocardial reserve. Based on the studies using dobutamine echocardiography to predict regional wall improvement after revascularization, we investigated the benefit of low-dose dobutamine radionuclide ventriculography for assessing functional contractile reserve in this population. The study group included 56 patients with ischemic cardiomyopathy (mean left ventricular [LV] ejection fraction [EF] of 23 +/- 5%) and multivessel disease, who were referred for viability assessment. All underwent radionuclide ventriculography before and during infusion of 5 and 10 microg/kg/min of dobutamine. An increase in global LVEF from rest to dobutamine was calculated, and 10% was considered the cutoff value to predict ventricular improvement after CABG. Of the 35 patients who underwent CABG 1 month later, 29 were available for repeated radionuclide ventriculography after 12 +/- 5 months. Of these, 15 showed improvement (delta LVEF > or = 5%, mean 10 +/- 5%) and 14 did not (delta LVEF < 5%, mean -1 +/- 3%). The increase in EF with dobutamine had the highest univariate predictive value of all parameters evaluated. The sensitivity, specificity, and positive and negative predictive values of dobutamine radionuclide ventriculography were 67%, 93%, 91%, and 72%, respectively. We conclude that dobutamine radionuclide ventriculography is a useful method to assess contractile reserve and predict ventricular functional improvement after CABG in patients with ischemic cardiomyopathy.